Last reviewed · How we verify
Lanreotide and Metformin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lanreotide and Metformin (Lanreotide and Metformin) — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lanreotide and Metformin TARGET | Lanreotide and Metformin | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lanreotide and Metformin CI watch — RSS
- Lanreotide and Metformin CI watch — Atom
- Lanreotide and Metformin CI watch — JSON
- Lanreotide and Metformin alone — RSS
Cite this brief
Drug Landscape (2026). Lanreotide and Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/lanreotide-and-metformin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab